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The transcriptional repressor Blimp-1 is considered the master regulator of plasma-cell differentia-
tion. In this issue of Immunity, Kallies et al. (2007) identify a Blimp-1-independent stage of differenti-
ation, followed by Blimp-1-dependent terminal differentiation.Triggered by the specific recognition of
exogenous antigen, a mature B cell is
activated and induced to differentiate
into an antibody-secreting plasma cell
that aids in pathogen elimination. In
acquired immunity processes, plasma
cells are selected and generated in
the germinal centers (GC) to secrete
high-affinity antibodies against T cell-
dependent antigens, or, in the case of
T cell-independent antigens, they are
generated extra-follicularly. Recent
studies are beginning to provide in-
sights into the molecular mechanisms
that govern plasma-cell differentiation.
The genesis of plasma cells is associ-
ated with the extinction of the tran-
scriptional program that establishes
the B cell phenotype, and this transi-
tion seems to be mediated by a net-
work of interacting transcriptional re-
pressors (Shapiro-Shelef and Calame,
2005). The role of master regulator of
plasma-cell differentiation has been
assigned to the transcription factor
Blimp-1 because it is able to induce
plasmablastic features in transfected
B cell lines in vitro (Turner et al.,
1994), and its ablation in mouse B cells
prevents the development of plasma
cells in vivo (Shapiro-Shelef and Cal-
ame, 2005). In addition to inducing
plasma-cell differentiation, it has been
suggested that Blimp-1 has a major
role in erasing the preplasma cell phe-
notypes by suppressing the transcrip-
tional repressors paired-box-protein 5
(Pax5), which is essential for commit-
ment of lymphoid progenitors to the B
cell lineage and thereafter actively
perpetuates ‘‘B cell identity,’’ and B
cell lymphoma protein 6 (BCL6), the
master regulator of GC B cells
(Shapiro-Shelef and Calame, 2005;
Ye et al., 1997). Blimp-1 is thought toact upstream of XBP-1, a transcription
factor required for the establishment of
the secretory phenotype of plasma
cells (Reimold et al., 2001; Shaffer
et al., 2004). Recently, IRF-4, a tran-
scription factor expressed in immature
B cells and re-expressed in GC centro-
cytes, has been identified as a second
master gene in plasma-cell differentia-
tion (Klein et al., 2006; Sciammas et al.,
2006). IRF-4 expression is likely to be
required upstream of XBP-1, but its
relationship with Blimp-1 expression
is unclear, having been reported either
upstream of (Sciammas et al., 2006) or
in parallel to (Klein et al., 2006) Blimp-1.
The role of Blimp-1 as a master reg-
ulator of plasma-cell differentiation is
now further elucidated by the results
of Kallies et al. (2007) in this issue of
Immunity. Their experimental system
is based on two critical features. First,
examination of Blimp-1 function in the
early phase of plasma-cell differentia-
tion by reconstituting lethally irradiated
Rag1/mice withPrdm1/ (the gene
encoding Blimp-1) fetal liver cells en-
sures that all B cells in the experimental
mice are Blimp-1 null, in contrast to
previously utilized conditional knock-
out mice in which Prdm1 deletion is in-
complete. Second, the insertion of the
gene encoding green fluorescent pro-
tein (GFP) into the disrupted Prdm1 lo-
cus allows the ability to track and iden-
tify the phenotype of Blimp-1-null cells.
By using this elegant experimental
system, Kallies et al. (2007) report two
main observations: (1) the initial step
of plasma-cell differentiation is inde-
pendent of Blimp-1, and instead re-
quires Blimp-1-independent downreg-
ulation of Pax5; and (2) this initial step
of plasma-cell differentiation is repre-
sentedbyanewly identifiedpreplasma-Immunblast phenotype that is characterized
by low immunoglobulin secretion.
The first observation is relevant be-
cause it suggests that the initiating sig-
nals for plasma-cell development must
be identified as ‘‘Pax5 inhibitory’’ as op-
posed to ‘‘Blimp-1 activating.’’ This no-
tion is consistent with the previous ob-
servation that experimentally induced
downregulation of Pax5 in B cells leads
to the upregulation of plasma-cell-
associated transcription factors, includ-
ing Blimp-1, and the establishment of
a plasma-cell program (Nera et al.,
2006; Delogu et al., 2006). The require-
ment for Pax5 inhibition suggests that
an active suppression of theBcell phe-
notype is as necessary for plasma-cell
differentiation as the actual induction
of a specific differentiation program. In
T cell-dependent GC-dependent re-
sponses, suppression of the B cell phe-
notype may also involve the specific
suppression of the GC phenotype via
downregulation of BCL6. Yet the ques-
tion remains as to which signal(s) and
molecule(s) are involved in Pax5 sup-
pression. Notably, Kallies et al. (2007)
show that Pax5 suppression is due to
inhibition of its function rather than to
downregulation of protein expression.
IRF-4 should be excluded as a candi-
date because IRF-4 transcription is not
induced in Prdm1-deficient preplas-
mablasts (Kallies et al., 2007), suggest-
ing that IRF-4 is downstream of Pax5
suppression (see below). Additional
relevant candidates including BCL6,
nuclear factor of activated T cells c1.2
(NFATc1.2), signal transducer andacti-
vator of transcription 3 (STAT3), the
OCA-B protein and Bach2, a member
of the BTB-basic region leucine zipper
(bZip) family, have not been conclu-
sively investigated in relation to theity 26, May 2007 ª2007 Elsevier Inc. 543
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PreviewsFigure 1. Step-wise Differentiation of an Activated B Cell into a Plasma Cell
Theupper pathway summarizes the current viewabout plasma-cell differentiation, i.e., thatBlimp-1
and IRF-4 act upstreamofXBP-1. The lower pathwaysummarizes the findingsofKallies et al. (2007)
in this issueof Immunity: anactivatedBcell instructed todifferentiate intoaplasmacell inhibitsPax5
function,which in turn releases thesuppressionofXbp1and thegeneencoding the joining (J)-chain,
resulting in low Ig secretion. Late in this preplasmablastic, Blimp-1-independent stage,Blimp-1 and
IRF-4 are upregulated independently, eventually resulting in the generation of the CD138+ plasma-
blast thatcontinues toproducesurface Igalongwithsecreted Ig.HighexpressionofXBP-1,Blimp-1,
and IRF-4, the exclusive production of secreted Ig, and the distinctive morphology, characterized
by large amount of cytoplasm, define the stage of the fully developed plasma cell.circuit leading to Pax5 functional si-
lencing, and may therefore represent
interesting targets for future studies.
The second important observation
by Kallies et al. (2007), i.e., the identifi-
cation of the preplasmablast as a stage
preceding terminal plasma-cell differ-
entiation, has important implications
for the regulation of this process. Al-
though transitory and experimentally
generated via Prdm1 deletion, the
newly identified preplasmablast phe-
notype is characterized by low immu-
noglobulin secretion and expression of
XBP-1 in the absence of detectable
amounts of both Blimp-1 and IRF-4 in-
duction in vitro. This is in contrast to
previous results showing that Blimp-1
and IRF-4 are both required for XBP-1
expression, thus suggesting the exis-
tence of additional pathways leading
to XBP-1 induction. Kallies et al. (2007)
suggest that Blimp-1, IRF-4, and
XBP-1 are independently regulated
proteins, all of which are required for
terminal plasma-cell differentiation
downstream of Pax5 inhibition. None-
theless, this model, which is summa-
rized in Figure 1 and is fully justified
by the data presented, does not ex-544 Immunity 26, May 2007 ª2007 Elsevplain the lack of XBP-1 induction in
IRF-4-deficient B cells in vitro (Klein
et al., 2006). Because the present
work did not quantify IRF-4 expression
in preplasmablasts, the presence of
low amounts of IRF-4 in those cells
can not be excluded. Finally, none of
the recently proposed models ad-
dresses the issue of the decision point
between plasma-cell and memory B
cell differentiation. An intriguing ques-
tion raised by the results of Kallies
et al. (2007) is whether Pax5 inactiva-
tion occurs before or after this decisive
point. Considering that memory B cells
retain the B cell phenotype, it is possi-
ble that, while Pax5 inactivation may
be the first step in the pathway of
plasma-cell differentiation, its contin-
ued expression may keep the cells in
the (memory) B cell phenotype.
In conclusion, the elegant work by
Kallies et al. (2007) is highly relevant in
that it identifies perhaps unexpected
steps in plasma-cell differentiation.
Vis a vis previous reports, these results
emphasize oncemore that different re-
sults can be obtained by different in-
vestigations, most likely as a result of
unavoidable variables and intrinsicier Inc.shortcomings of the currently available
experimental systems. For instance,
in vitro differentiation assays are typi-
cally performed on B cells at various
developmental stages, none of which
may be representative of the physio-
logic targets of plasma-cell differentia-
tion (e.g., GC B cells), and most of
which are heterogeneous in their de-
gree of circuit activation. Also, the
stimuli utilized for in vitro differentiation
assays may not precisely reflect the
in vivo situation. Finally, although infor-
mative and presently without alterna-
tives, analysis based on single-gene
ablation and models based on linear
representations fall short of unraveling
the complex feedback and feedfor-
ward circuits that likely regulate cell
behavior. Thus, progress is clearly be-
ing made, but inconsistencies in find-
ings should be expected until systems
biology can eventually find its way into
the study of plasma-cell differentiation.
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